For patients with diabetes, a systolic target of 120 mm Hg led to a significant reduction in CV events in BPROADS, mirroring ...

A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...

Pharmacy spend is becoming a key value lever at US portfolio companies as PE firms up their focus on healthcare oversight, ...

Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention.

The urine samples from the high BMI group showed elevated levels of metabolites of the amino acid histidine, corroborating the observations of other researchers who found a similar increase in ...

Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of ...

“By combining advanced biomaterials science with practical clinical applications, we’re opening new possibilities for ...

An AI program trained to spot a leading type of the disease, called metabolic-associated steatotic liver disease (MASLD), unearthed hundreds of undiagnosed cases among the electronic health records of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A study of almost 13,000 adults with Type 2 diabetes and high systolic blood pressure assessed if a more intensive treatment ...

Obesity in the United States has continued to rise for decades even in the face of increased awareness and access to healthy ...